A Message from NCTracks on Behalf of NC Medicaid Relyvrio End of Coverage and Removal from NC Medicaid Preferred Drug List (PDL)

Amylyx Pharmaceuticals has formally announced that Relyvrio (sodium phenylbutyrate and taurursodiol) is no longer available to new patients as of April 4, 2024. Amylyx has initiated a process with the U.S. Food and Drug Administration (FDA) to voluntarily discontinue the drug and remove it from the market.

According to a press release from the manufacturer, patients currently receiving treatment who, in consultation with their physician, wish to continue can be transitioned to a free drug program.

As a result of this announcement, Relyvrio is no longer covered at point-of-sale, effective April 4, 2024 and the product will be removed from the NC Medicaid Preferred Drug List (PDL).